The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
about
Involvement of autophagy in ovarian cancer: a working hypothesisThe PI3K pathway as drug target in human cancerDiverse mechanisms of AKT pathway activation in human malignancyWill targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Cancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domainDiscovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity.Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.Genetics of endometrial cancersPhosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic.Akt1 deletion prevents lung tumorigenesis by mutant K-ras.A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.Protein mislocalization: mechanisms, functions and clinical applications in cancer.Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomasRegulation of Akt signaling activation by ubiquitination.Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registryHigh frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stabilityInfluence of AKT on progesterone action in endometrial diseases.Association between AKT1 Gene Polymorphism rs2498794 and Smoking-Related Traits with reference to Cancer Susceptibility.Personalized therapy in endometrial cancer: challenges and opportunities.Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.K63-linked ubiquitination in kinase activation and cancer.AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.The genomics and genetics of endometrial cancer.Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinomaWhole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.Mutant AKT1-E17K is oncogenic in lung epithelial cellsRational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowPrognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. BroaddusFive endometrial cancer risk loci identified through genome-wide association analysis.A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 BindingPersonalized care in uterine cancer.Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
P2860
Q21198790-89BEBD73-2A73-42F8-84FF-41FBFFBDE1DAQ24632283-EE158867-6429-4625-BEEF-A8D9302FC460Q26851604-434A15CD-696D-4723-AF3B-05B804C6B8C3Q28078957-7A5C3F4A-AEA7-45E4-B20B-3A87693E0E22Q28080599-C88A2AB5-2F86-4046-806D-3F4EC8409BFCQ28533515-446E81DA-2602-4FF0-95A4-67B8ED62CC6CQ28540161-295E0F85-D349-403C-B517-13E8202674C1Q28550300-18A686C2-F3FA-40C0-9B47-FC6BF8CA0226Q30838969-3BA4CE9E-726E-4152-8A6D-101557C0B6EBQ33557916-B4CD3B81-C1A8-498C-A129-B08B38FB17CAQ33637346-20981207-82D9-4EA1-B6D1-8B94C9AD852DQ33781274-67A92B31-70B9-4B51-99BE-929AD68DF4A3Q33823535-09071802-AE47-4870-AA0E-929E920D022EQ34049042-50862693-EB5F-434F-B187-5B984EBB00B4Q34062367-6967EC39-12B2-4AA9-95C9-F014A506E0DFQ34076405-5A2EF504-CF23-4639-9938-E42959BDFBDDQ34291001-F5351F9A-BF7C-48B9-8440-4EE624D70745Q34592027-B4CB0C7D-AD1A-4A49-8020-9D9353F29D03Q34694344-4AC60DC7-B457-4BDF-BD65-1A0840C241C6Q34799443-6710B0BA-02C8-4E84-A65E-455EC46012BEQ34976598-FF84F401-93CC-4521-BDEE-BD80F606BA60Q35169273-9572E089-3D11-4023-97CF-86D28D2EE12DQ35275603-251A1CB4-CFB4-4478-B66B-3B06573A5BF4Q35617565-E8DC8118-F001-4535-A157-1B8159AA40BCQ35763163-2C3AED62-B226-40F0-A701-8EF358FD82CEQ35911350-2CF0687A-0FF4-4D73-904D-02D2E175F0FEQ35926060-097FB792-B05A-4168-B16A-1DCB8488654AQ35971438-28A0C1FC-B00C-4B1A-A60E-6FB23A229483Q36101969-FB0EF1FB-892F-4964-8C8F-528260F1FED9Q36151896-BE6A951D-233D-4DB6-9483-2AE815646495Q36335709-C81121AC-DF01-466F-9881-BE152547A590Q36354855-D12314A7-DEA6-4BAE-AC41-199D1F2156FEQ36545440-A0F107EA-05E6-4183-B0DF-FB55A7E69D3EQ36731185-77ADE964-74FE-4A4A-BFB2-1117160DDF12Q36750990-8A23FC18-1FD5-4010-AC1F-084F6224FF1DQ36841899-FC70CDCF-CD0E-40F5-BBF4-863BDFEBBBD7Q37002930-8416DA9C-3193-4801-866E-F7396E7D75AAQ37005064-0B338509-5A5D-4E01-AFF2-0FC4F1888902Q37006856-E50DF11C-330A-4DC0-B0A3-2ABE172F0E03Q37109462-8B74ED47-213C-414C-A6EE-5EB464EE9210
P2860
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The oncogenic mutation in the ...... KT1 in endometrial carcinomas.
@en
The oncogenic mutation in the ...... KT1 in endometrial carcinomas.
@nl
type
label
The oncogenic mutation in the ...... KT1 in endometrial carcinomas.
@en
The oncogenic mutation in the ...... KT1 in endometrial carcinomas.
@nl
prefLabel
The oncogenic mutation in the ...... KT1 in endometrial carcinomas.
@en
The oncogenic mutation in the ...... KT1 in endometrial carcinomas.
@nl
P2093
P2860
P356
P1476
The oncogenic mutation in the ...... KT1 in endometrial carcinomas.
@en
P2093
H Aburatani
H Kuramoto
O Hiraike-Wada
S Hosokawa
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605109
P407
P577
2009-06-02T00:00:00Z